Floatz logo

Palbociclib

Recurrent Thyroid Gland Carcinoma

University Medical Center GroningenSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the Recurrent Thyroid Gland Carcinoma cohort.

Asset / SponsorPhaseRating
LENVATINIB
University Medical Center Groningen
Phase 4BB
Olaparib
University Medical Center Groningen
Phase 4BB
gw786034
University Medical Center Groningen
Phase 4B
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC
Larotrectinib
National Cancer Institute (NCI)
Phase 2CCC

View all 39 →

Same molecule, other indications

Palbociclib is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →